The drug resistance of Candida albicans (C. albicans), resulted from gradual application of advanced medical treatments and the widespread use of antifungals, has become a severe problem in clinic. C. albicans is one of the major opportunistic human fungal pathogens. The transition from yeast to hypha is a necessary process in its pathogenic activity, and inhibiting the hypha formation can decrease its infective ability. Quorum sensing signal BDSF (short­-chain fatty acid) from Burkholderiacenocepacia can inhibit the yeast­to­hypha transition and hinder the virulence of C. albicans. The drug susceptibility of 60 C.albicans clinical isolates to fluconazole and BDSF were determined respectively. The results showed there were 8 strains (13.3%) resistant to fluconazole, with the minimum inhibitory concentration (MIC) ≥64 μg/ml, but BDSF showed efficiently inhibitory effect on all the clinical isolates no matter the isolates were resistant to fluconazole or not. The results suggest that BDSF might be a new clinical option to treat C. albicans infection.